Lactococcus lactis Strains Enhance Intestinal Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal disorders such as Irritable Bowel Syndrome (IBS), Post-Infectious IBS, and Inflammatory Bowel Diseases (IBD) are inadequate in addressing the underlying inflammation and microbial imbalance, with limited evidence on the effectiveness of Lactococcus lactis strains in improving intestinal barrier integrity and inhibiting pathogenic bacteria.
Innovation Solution
The use of specific Lactococcus lactis strains, namely DN 030 066 and DN 030 087, which have been shown to enhance epithelial barrier integrity and exhibit antimicrobial activity against pathogenic Enterobacteriaceae, are employed to treat and prevent digestive disorders by inhibiting pathogenic microorganism growth and improving intestinal health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for gastrointestinal disorders, then symptoms may be temporarily managed, but the underlying inflammation and microbial imbalance are not effectively addressed
Solution Approach 1:
The patent introduces Lactococcus lactis strains as intermediary organisms that mediate between the host immune system and pathogenic bacteria. These probiotic strains act as beneficial intermediaries that restore microbial balance, reduce inflammation through immunomodulation, and compete with pathogenic Enterobacteriaceae for resources and attachment sites, thereby effectively addressing both inflammation and microbial imbalance simultaneously
2Reliability
If Lactococcus lactis strains are used to inhibit pathogenic bacteria, then intestinal barrier integrity is improved, but specific strain selection and standardization are required
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing specific Lactococcus lactis strains (DN 030 066 and DN 030 087) with defined phenotypic and genotypic parameters. These strains exhibit specific characteristics including bacteriocin production capabilities, adhesion properties, and immunomodulatory effects. By establishing standardized parameters for strain selection and characterization, the patent resolves the complexity issue while ensuring reliable improvement of intestinal barrier integrity
3Ease of operation
If probiotic strains are administered to treat digestive disorders, then symptoms of IBS, PI-IBS, and IBD are alleviated, but evidence on effectiveness against specific pathogenic mechanisms is limited
Solution Approach 1:
The patent implements feedback mechanisms through in vitro and in vivo validation of the selected Lactococcus lactis strains. The strains are tested against specific pathogenic mechanisms including inhibition of Enterobacteriaceae growth, modulation of inflammatory cytokines, and enhancement of tight junction proteins. This systematic feedback validation provides precise evidence of effectiveness while maintaining ease of operation through standardized administration protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These strains effectively improve intestinal barrier function and inhibit pathogenic bacteria, providing relief from symptoms of IBS, PI-IBS, and IBD by enhancing the epithelial barrier and reducing inflammation.
Implementation Method 1
exhibit antimicrobial activity against pathogenic Enterobacteriaceae
Implementation Method 2
enhance epithelial barrier integrity and exhibit antimicrobial activity
Data Source
AI summary
The present invention concerns strains of Lactococcus lactis capable of inhibiting the growth of a pathogenic microorganism and/or improving the intestinal epithelial barrier integrity. These strains are suitable for use in the treatment or prevention of a digestive disorder.